Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease

Jeffrey T-J Huang (Lead / Corresponding author), Rekha Chaudhuri, Osama Albarbarawi, Alun Barton, Christal Grierson, Petra Rauchhaus, Christopher J. Weir, Martina Messow, Nicola Stevens, Charles McSharry, Giora Feuerstein, Somnath Mukhopadhyay, Jeffrey Brady, Colin N. A. Palmer, Douglas Miller, Neil C. Thomson

Research output: Contribution to journalArticle

47 Citations (Scopus)
133 Downloads (Pure)

Abstract

Background: Although an increased concentration of degraded elastin products in patients with chronic obstructive pulmonary disease (COPD) has been reported for many years, its clinical validity and utility remain uncertain due to technical difficulties, small study groups and the unknown relationship between exacerbation and elastin degradation. The objectives of this study were to determine the validity of urinary and blood total desmosine/isodesmosine in patients with COPD and asthma and to evaluate their relationship to exacerbation status and lung function.
Methods: Urinary and blood desmosine levels were measured using validated isotopic dilution liquid chromatography-tandem mass spectrometry methods.
Results: 390 study participants were recruited from the following groups: healthy volunteers, stable asthma, stable and 'during an exacerbation' COPD. Compared with healthy non-smokers, we found increased urinary or blood desmosine levels in patients with COPD, but no differences in patients with asthma or healthy smokers. The elevation of urinary desmosine levels was associated with the exacerbation status in patients with COPD. Approximately 40% of patients with stable and 'during an exacerbation' COPD showed elevated blood desmosine levels. Blood desmosine levels were strongly associated with age and were negatively correlated with lung diffusing capacity for carbon monoxide.
Conclusion: The results suggest that urinary desmosine levels are raised by exacerbations of COPD whereas blood desmosine levels are elevated in a subgroup of patients with stable COPD and reduced lung diffusing capacity. The authors speculate that a raised blood desmosine level may identify patients with increased elastin degradation suitable for targeted therapy. Future prospective studies are required to investigate this hypothesis. Copyright Article author (or their employer) 2012.
Original languageEnglish
Pages (from-to)502-508
Number of pages7
JournalThorax
Volume67
Issue number6
DOIs
Publication statusPublished - 16 Jan 2012

Fingerprint Dive into the research topics of 'Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

  • Equipment

  • Cite this

    Huang, J. T-J., Chaudhuri, R., Albarbarawi, O., Barton, A., Grierson, C., Rauchhaus, P., Weir, C. J., Messow, M., Stevens, N., McSharry, C., Feuerstein, G., Mukhopadhyay, S., Brady, J., Palmer, C. N. A., Miller, D., & Thomson, N. C. (2012). Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax, 67(6), 502-508. https://doi.org/10.1136/thoraxjnl-2011-200279